文献速递血脂与心血管预防冠心病

FOURIER 试验:自身免疫或炎症性疾病患者中依洛尤单抗强化降 LDL-C 的疗效分析

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
PubMed 文献 · Circulation · 2025-04-21

FOURIER 试验随机纳入 27 564 例稳定动脉粥样硬化且正在服用他汀的患者,比较依洛尤单抗与安慰剂。基线时 889 例(3.2%)合并自身免疫或炎症性疾病(AIID)。依洛尤单抗在合并 AIID 患者中降低主要终点事件的相对幅度可能更大(HR 0.58 vs 0.86,交互 P=0.066),关键次要终点交互 P=0.022。

要点

  • 合并 AIID 患者基线 hsCRP 更高,依洛尤单抗未显著改变 hsCRP。
  • 依洛尤单抗降低 LDL-C 百分比在合并与不合并 AIID 患者中一致。
  • 合并 AIID 患者主要终点事件相对降幅更大,但交互检验未达统计学显著。

核心结论

  • 依洛尤单抗强化降低 LDL-C 可能使合并 AIID 患者获得更大的心血管事件相对降幅。

研究设计与样本

  • FOURIER 为随机对照试验,纳入 27 564 例服用他汀的稳定动脉粥样硬化患者,比较依洛尤单抗与安慰剂。
  • 本分析按有无 AIID 分组,AIID 定义为任何自身免疫或慢性炎症性疾病。

主要发现

  • 基线时 889 例(3.2%)合并 AIID,最常见为类风湿关节炎(33.7%)和银屑病(15.6%)。
  • 合并与不合并 AIID 患者的中位 LDL-C 分别为 90.0 mg/dL(79.5-105.5)和 91.5 mg/dL(79.5-108.5),P=0.025。
  • 依洛尤单抗安慰剂校正的 LDL-C 降幅在合并与不合并 AIID 患者中分别为 60.2% 和 59.0%,P=0.57。
  • 合并 AIID 患者基线 hsCRP 更高(中位 2.1 vs 1.7 mg/L,P<0.001),依洛尤单抗未显著改变两组 hsCRP。
  • 依洛尤单抗降低主要终点事件:不合并 AIID 者 HR 0.86(95%CI 0.80-0.93),合并 AIID 者 HR 0.58(95%CI 0.38-0.89),交互 P=0.066。

临床怎么用

  • 对合并 AIID 的动脉粥样硬化患者,可考虑依洛尤单抗强化降 LDL-C 以降低心血管事件风险。

局限性

  • AIID 亚组样本量较小(889 例),主要终点交互检验未达统计学显著(P=0.066)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events. METHODS: FOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients with stable atherosclerosis who were taking statins. This analysis focused on the effect of evolocumab in patients with or without an AIID, defined as any autoimmune or chronic inflammatory condition. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization. RESULTS: At baseline, 889 patients (3.2%) had an AIID, most commonly rheumatoid arthritis (33.7%) or psoriasis (15.6%). Median (interquartile range) low-density lipoprotein cholesterol levels were 90.0 mg/dL (79.5-105.5) and 91.5 mg/dL (79.5-108.5) in patients with or without an AIID, respectively (P=0.025), and the placebo-adjusted percent reduction with evolocumab was consistent (60.2% versus 59.0%; P=0.57). Baseline hsCRP was higher in patients with an AIID (median 2.1 versus 1.7 mg/L; P<0.001) and did not significantly change with evolocumab in either group. Compared with placebo, evolocumab reduced the rate of the primary end point by 14% in patients without an AIID (hazard ratio, 0.86 [95% CI, 0.80-0.93]) and by 42% in patients with an AIID (hazard ratio, 0.58 [95% CI, 0.38-0.89]; Pinteraction=0.066). Likewise, evolocumab reduced the key secondary end point of cardiovascular death, myocardial infarction, or stroke by 19% in patients without an AIID (hazard ratio, 0.81 [95% CI, 0.74-0.89]) and 58% in those with an AIID (hazard ratio, 0.42 [95% CI, 0.24-0.74]; Pinteraction=0.022). CONCLUSIONS: Intensive lowering of low-density lipoprotein cholesterol levels with evolocumab may lead to greater relative reduction in cardiovascular events in patients with an AIID. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01764633.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zimerman A, Kunzler ALF, Weber BN, et al. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025. PMID: 40255182. doi:10.1161/CIRCULATIONAHA.124.072756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。